| 16.25 0.09 (0.56%) | 09-15 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 21.58 | 1-year : | 23.82 |
| Resists | First : | 18.47 | Second : | 20.39 |
| Pivot price | 16.94 |
|||
| Supports | First : | 15.36 | Second : | 12.78 |
| MAs | MA(5) : | 16 |
MA(20) : | 17.13 |
| MA(100) : | 15.69 |
MA(250) : | 11.06 |
|
| MACD | MACD : | -0.6 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 14.4 |
D(3) : | 11.7 |
| RSI | RSI(14): 41.7 |
|||
| 52-week | High : | 24.28 | Low : | 1.64 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ERAS ] has closed above bottom band by 35.1%. Bollinger Bands are 18% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 16.31 - 16.38 | 16.38 - 16.44 |
| Low: | 15.37 - 15.45 | 15.45 - 15.51 |
| Close: | 16.13 - 16.25 | 16.25 - 16.36 |
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
Tue, 15 Sep 2026
Erasca, Inc. (NASDAQ: ERAS) foundation plans another ERAS stock sale - Stock Titan
Tue, 15 Sep 2026
Attention Long-Term Shareholders of Erasca, Inc. (NASDAQ: - GlobeNewswire
Mon, 14 Sep 2026
ERAS Stock Slumps Nearly 40% After-Hours: Fine Print In 'Positive' Cancer Trial Reveals Treatment-Related Death - Stocktwits
Tue, 08 Sep 2026
Erasca, Inc. (NASDAQ:ERAS) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Wed, 02 Sep 2026
Long-Term Shareholders of Erasca, Inc. (ERAS) Are Encouraged to Contact Johnson Fistel Regarding Potential Claims - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 350 (M) |
| Shares Float | 243 (M) |
| Held by Insiders | 9.4 (%) |
| Held by Institutions | 86.3 (%) |
| Shares Short | 30,850 (K) |
| Shares Short P.Month | 30,770 (K) |
| EPS | -0.95 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.15 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -21.4 % |
| Return on Equity (ttm) | -78.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.43 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -98 (M) |
| Levered Free Cash Flow | -210 (M) |
| PE Ratio | -17.11 |
| PEG Ratio | 0 |
| Price to Book value | 14 |
| Price to Sales | 0 |
| Price to Cash Flow | -57.99 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|